Sándor Szunyogh

Sándor Szunyogh


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2025 in Molecular Therapy
Verified
Journal Article
Open access
SSSándor Szunyogh
Sándor Szunyogh
ECEmily Carroll
Emily Carroll
RWRichard Wade-Martins
Richard Wade-Martins
Parkinson's disease (PD) is a progressive, neurodegenerative disorder for which there is currently no cure. Gene therapy has emerged as a novel approach offering renewed hope for the development of treatments that meaningfully alter the course of the disease. In this review we explore various gene therapy strategies currently being developed targeting key aspects of PD pathogenesis: the restoration of the dopamine system by delivering genes involved in dopamine biosynthesis; reinforcing the inhibitory signalling pathways through glutamic acid decarboxylase (GAD) delivery to increase GABA production; enhancing neuronal survival and development by introducing various neurotrophic factors; delivery of genes to complement recessive familial PD mutations to correct mitochondrial dysfunction; restoring lysosomal function through delivery of GBA1 to increase glucocerebrosidase (GCase) activity; and reducing alpha-synuclein levels by reducing or silencing SNCA expression. Despite promising early work, challenges remain in developing safe, effective, and long-lasting gene therapies. Key considerations include optimizing viral vectors for targeted delivery, achieving controlled and sustained gene expression using different promoters, minimizing immune responses and increasing transgene delivery capacity. Future prospects may involve combinatory strategies targeting multiple pathways, such as multi-gene constructs delivered via high-capacity viral systems.

4 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
JOJudit Oláh
Judit Oláh
ALAttila Lehotzky
Attila Lehotzky
SSSándor Szunyogh
Sándor Szunyogh
STSzénási Tibor
Szénási Tibor
Ferenc OroszFerenc Orosz
Ferenc Orosz
JOJudit Ovádi
Judit Ovádi
The sensing, integrating, and coordinating features of the eukaryotic cells are achieved by the complex ultrastructural arrays and multifarious functions of the cytoskeleton, including the microtubule network. Microtubules play crucial roles achieved by their decoration with proteins/enzymes as well as by posttranslational modifications. This review focuses on the Tubulin Polymerization Promoting Protein (TPPP/p25), a new microtubule associated protein, on its “regulatory functions by day and pathological functions at night”. Physiologically, the moonlighting TPPP/p25 modulates the dynamics and stability of the microtubule network by bundling microtubules and enhancing the tubulin acetylation due to the inhibition of tubulin deacetylases. The optimal endogenous TPPP/p25 level is crucial for its physiological functions, to the differentiation of oligodendrocytes, which are the major constituents of the myelin sheath. Pathologically, TPPP/p25 forms toxic oligomers/aggregates with α-synuclein in neurons and oligodendrocytes in Parkinson’s disease and Multiple System Atrophy, respectively; and their complex is a potential therapeutic drug target. TPPP/p25-derived microtubule hyperacetylation counteracts uncontrolled cell division. All these issues reveal the anti-mitotic and α-synuclein aggregation-promoting potency of TPPP/p25, consistent with the finding that Parkinson’s disease patients have reduced risk for certain cancers.

23 April 2018 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Open access
SSSören Swyter
Sören Swyter
MSMatthias Schiedel
Matthias Schiedel
DMDaria Monaldi
Daria Monaldi
SSSándor Szunyogh
Sándor Szunyogh
ALAttila Lehotzky
Attila Lehotzky
MJManfred Jung
Manfred Jung
Sirtuins are NAD + -dependent protein deacylases capable of cleaving off acetyl as well as other acyl groups from the ɛ-amino group of lysines in histones and other substrate proteins. They have been reported as promising drug targets, and thus modulators of their activity are needed as molecular tools to uncover their biological function and as potential therapeutics. Here, we present new assay formats that complement existing assays for sirtuin biochemistry and cellular target engagement. Firstly, we report the development of a homogeneous fluorescence-based activity assay using unlabelled acylated peptides. Upon deacylation, the free lysine residue reacts with fluorescamine to form a fluorophore. Secondly, using click chemistry with a TAMRA-azide on a propargylated sirtuin inhibitor, we prepared the first fluorescently labelled small-molecule inhibitor of Sirt2. This is used in a binding assay, which is based on fluorescence polarization. We used it successfully to map potential inhibitor-binding sites and also to show cellular Sirt2 engagement. By means of these new assays, we were able to identify and characterize novel Sirt2 inhibitors out of a focused library screen. The binding of the identified Sirt2 inhibitors was rationalized by molecular docking studies. These new chemical tools thus can enhance further sirtuin research. This article is part of a discussion meeting issue ‘Frontiers in epigenetic chemical biology'.

1 April 2014 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
NTNatália Tőkési
Natália Tőkési
JOJudit Oláh
Judit Oláh
EHEmma Hlavanda
Emma Hlavanda
SSSándor Szunyogh
Sándor Szunyogh
ASAdél Szabó
Adél Szabó
JOJudit Ovádi
Judit Ovádi

1 January 2017 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
STSzénási Tibor
Szénási Tibor
JOJudit Oláh
Judit Oláh
ASAdél Szabó
Adél Szabó
SSSándor Szunyogh
Sándor Szunyogh
ALAndrás Láng
András Láng
JOJudit Ovádi
Judit Ovádi

6 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAdél Szabó
Adél Szabó
JOJudit Oláh
Judit Oláh
SSSándor Szunyogh
Sándor Szunyogh
ALAttila Lehotzky
Attila Lehotzky
STSzénási Tibor
Szénási Tibor
JOJudit Ovádi
Judit Ovádi
The microtubule network exerts multifarious functions controlled by its decoration with various proteins and post-translational modifications. The disordered microtubule associated Tubulin Polymerization Promoting Protein (TPPP/p25) and the NAD+-dependent tubulin deacetylase sirtuin-2 (SIRT2) play key roles in oligodendrocyte differentiation by acting as dominant factors in the organization of myelin proteome. Herein, we show that SIRT2 impedes the TPPP/p25-promoted microtubule assembly independently of NAD+; however, the TPPP/p25-assembled tubulin ultrastructures were resistant against SIRT2 activity. TPPP/p25 counteracts the SIRT2-derived tubulin deacetylation producing enhanced microtubule acetylation. The inhibition of the SIRT2 deacetylase activity by TPPP/p25 is evolved by the assembly of these tubulin binding proteins into a ternary complex, the concentration-dependent formation of which was quantified by experimental-based mathematical modelling. Co-localization of the SIRT2-TPPP/p25 complex on the microtubule network was visualized in HeLa cells by immunofluorescence microscopy using Bimolecular Fluorescence Complementation. We also revealed that a new potent SIRT2 inhibitor (MZ242) and its proteolysis targeting chimera (SH1) acting together with TPPP/p25 provoke microtubule hyperacetylation, which is coupled with process elongation only in the case of the degrader SH1. Both the structural and the functional effects manifesting themselves by this deacetylase proteome could lead to the fine-tuning of the regulation of microtubule dynamics and stability.